<DOC>
	<DOCNO>NCT02952599</DOCNO>
	<brief_summary>According current guideline , duration anticoagulant treatment venous thromboembolic event varies 3 month indefinite treatment depend estimate risk venous thromboembolism ( VTE ) recurrence bleeding . Current data edoxaban limit maximum treatment duration 12 month . Therefore , study aim gather insight efficacy ( i.e . symptomatic recurrent VTE ) safety ( i.e . bleed event , liver adverse event , all-cause mortality drug relate adverse event ) extend treatment edoxaban 12 month unselected patient population routine clinical practice .</brief_summary>
	<brief_title>Edoxaban Treatment Routine Clinical Practice Patients With Venous Thromboembolism Korea Taiwan ( ETNA-VTE-KOR-TWN )</brief_title>
	<detailed_description>Edoxaban orally administer anticoagulant inhibits coagulation factor Xa . It approve Ministry Food Drug Safety ( MFDS ) Korea ( date : 25th , August 2015 ) : Reduction risk stroke systemic embolism patient non valvular atrial fibrillation ( NVAF ) Treatment deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) Reduction risk recurrent DVT PE , Taiwan Food Drug Administration ( TFDA ) Taiwan ( date : 24th , February , 2016 ) Prevention stroke systemic embolism adult patient NVAF one risk factor , congestive heart failure , hypertension , age â‰¥ 75 year , diabetes mellitus , prior stroke transient ischemic attack ( TIA ) . Treatment deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) follow 5 10 day initial therapy parenteral anticoagulant . According current guideline , duration anticoagulant treatment venous thromboembolic event varies 3 month indefinite treatment depend estimate risk venous thromboembolism ( VTE ) recurrence bleeding . Current data edoxaban limit maximum treatment duration 12 month . This non-interventional study aim gather insight efficacy ( i.e . symptomatic recurrent VTE ) safety ( i.e . bleed event , liver adverse event , all-cause mortality drug relate adverse event ) extend treatment edoxaban 12 month approximately 350 patient unselected patient population routine clinical practice .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Established acute initial recurrent VTE Patients prescribe treatment edoxaban accord package information participation trial Written inform consent participation study ( ICF ) Not simultaneously participate interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non-interventional Study</keyword>
	<keyword>Real World Evidence</keyword>
	<keyword>Patients Acute VTE treat Edoxaban</keyword>
	<keyword>Efficacy/Safety</keyword>
</DOC>